Viome celebrates raising $86.5 Million in series C Funding, alongside Gut Test launch
Viome Life Sciences has concluded an oversubscribed Series C funding round, amassing $86.5 million and boosting its total funding to $175 million.
Concluding an oversubscribed Series C Funding
This investment round witnessed the participation of Bold Capital and Khosla Ventures, joining both existing and new investors in supporting Viome’s endeavours.
In a strategic move, Viome is rolling out its pioneering Gut Intelligence Test across 200 CVS locations. This advancement comes as a significant step forward in the company’s mission to promote personalized wellness.
Viome’s ground-breaking approach involves offering a comprehensive body intelligence test, empowering users with personalized dietary suggestions and the creation of tailor-made supplements and probiotics—developed and distributed by Viome itself. Furthermore, Viome extends its scope with an oral health intelligence test, incorporating VRx My·Biotics Oral Lozenges designed to evaluate and enhance oral bacterial health.
Enhancing wellness through gut health
At the heart of the Washington-based company’s initiative is the Gut Intelligence Test, available both in-store at CVS locations and online. This assessment covers a range of parameters, including digestive efficiency, gut lining health, gas production, protein fermentation, inflammatory activity, metabolic fitness, gut active microbial diversity, and microbiome-induced stress. The overarching goal is to provide individuals with insights into their gut health, along with recommendations for suitable probiotic strains and prebiotic fibres.
The substantial proceeds from the Series C funding will be directed towards advancing research and development of Viome’s suite of health assessment tools, as well as its expansion into retail channels.
Naveen Jain, Viome’s founder and CEO, commented on the significance of this milestone, stating, “Amidst the surge in chronic conditions and the influx of conflicting dietary advice flooding social media, it became evident that a seismic shift was necessary. At Viome, we’re not just talking about wellness; we are creating a whole new understanding of what it means to be healthy by addressing the root cause of issues and not just the symptoms.
“By combining our deep understanding of individual uniqueness and the microbiome with cutting-edge RNA sequencing and AI technology, we’re able to translate data into actionable insights that can profoundly impact our health span and lifespan. I feel grateful to have the support of investors and partners who truly understand and appreciate our ground-breaking work.
“The latest funding and our expansion into CVS represent more than just business milestones; they’re a testament to our commitment and an opportunity for us to accelerate our learning as we get closer to achieving our mission of helping billions of people live better lives,” Naveen Jain, founder and CEO of Viome, told MobiHealthNews in an email.
Viome’s legacy of financial triumphs
Viome’s trajectory has been punctuated by previous financial achievements, including a pre-Series C convertible funding round that raised $54 million in 2021, a Series B funding round of $56 million in 2019, and $15 million secured in August 2017.
Viome achieved a noteworthy milestone in 2021 when it received FDA breakthrough device designation for its mRNA analysis technology and AI platform. This platform demonstrates an ability to detect early indications of oral and throat cancer through user saliva samples.
The home testing market is marked by players like Reperio Health, the provider of a connected home wellness assessment kit aimed at employers, as well as home diagnostics companies such as Cue Health and Everly Health. The latter includes EverlyWell, an at-home diagnostics start-up, and Natalist, which specializes in pregnancy and fertility-focused solutions.”
Embark On An Exciting Tour Of Everything Med-Tech!
This forthcoming October, seize the opportunity to be a part of an extraordinary journey at the Med-tech World Summit in Malta. Uncover the forefront of Medical Technology, Digital Health, AI in medicine, and other emerging breakthroughs during this distinguished event, where prominent researchers and forward-thinking visionaries converge. Immerse yourself in an array of highly anticipated networking avenues, enlightening conferences, and an expansive exhibition floor teeming with top-notch exhibitors and innovative start-ups.
In the interim, stay well-informed about the latest developments in Med-Tech and Digital Health. Stay ahead of the curve with up-to-the-minute updates from Med-Tech News, and delve into captivating feature articles found within the pages of the newest edition of BLOCK Magazine.
you might also like
21st February 2024
One million benefit from ClinicY’s patient-centric digital health solutions
20th February 2024